Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus

The Catholic University of Korea24 enrolled

Overview

The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor

Sitagliptin, a DPP-4 inhibitor was used as an incretin enhancer in clinical practice first. In clinical trials, sitagliptin showed effective control of blood glucose level in type 2 diabetes and 100 mg once daily with metformin was similar to sulfonylurea (glipizide) with metformin in lowering HbA1c. Mostly in practice, stable blood glucose levels were maintained after change of sulfonylurea to sitagliptin in type 2 diabetes treatment. However, in some cases, there were abrupt severe hyperglycemia and uncontrolled blood glucose level after drug change to sitagliptin. Several mechanism could be considered for reduced response to DPP-4 inhibitor in some type 2 diabetes patients. Firstly, significantly reduced secretion of glucagon-like peptide 1 (GLP-1) more than expected in diabetes or functional defect of GLP-1 activity could be the mechanism of loss of GLP-1 effect irrespective of DPP-4. Secondly, mutation or functional defect of DPP-4 enzyme could not be inhibited by DPP-4 inhibitor. Thirdly, GLP-1 receptor mutation or other defect in β-cell responsiveness to GLP-1 leads to reduction of response to DPP-4 inhibitor.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type 2 Diabetes Mellitus

Interventions

SitagliptinDRUG

Sitagliptin (100mg, per oral) once a day.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetic patients with less than 15 yrs of disease duration * BMI between 22-27 kg/m2 * HbA1c ≤ 9% at recruitment 1. Study group After change sulfonylurea to sitagliptin in case of metformin and sulfonylurea therapy 1. Increase of fasting blood glucose over 20 mg/dL or postprandial glucose over 30 mg/dL within several days or 2. Increase of HbA1c over 1% within 2-3 months without abrupt increase of blood glucose levels within several days * Sulfonylurea dose : less than glimepiride 4mg or gliclazide 120mg or glibenclamide 10mg * Metformin dose : 500\~2000mg 3. Reduced response to sitagliptin should be made a decision by investigators after understanding the condition of patients surely. 2\. Control group * Age, sex, BMI matched patients with same condition of study patients * After change sulfonylurea to sitagliptin in case of metformin plus sulfonylurea therapy, no change of blood glucose levels like above or stable HbA1c change within 1% within 2-3 months Exclusion Criteria: * Other causes of increase of blood glucose levels except drug change * Patients with history of insulin treatment * Patients taking thiazolidinediones, alpha-glucosidase inhibitors, GLP-1 analogue or DPP-4 inhibitors * Patients with renal, hepatic dysfunction * Patients with diabetic complications such as coronary heart disease, cerebrovascular disease, proliferative diabetic retinopathy or diabetic gastroparesis * Patients taking medications affecting glucose level

Locations (2)

The Catholic University of Korea; St.Paul's Hospital

Seoul, South Korea

The Catholic University of Korea; Seoul St. Mary's Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Plasma Concentration of Active Glucagon-like Peptide 1 (GLP-1) Before and After Sitagliptin Treatment

Plasma concentrations of active GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test (MTT). Second measurement of active GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.

Time frame: 0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose

Plasma Concentration of Total GLP-1 Before and After Sitagliptin Treatment

Plasma concentrations of total GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.

Time frame: 0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose

Plasma Concentration of Total Glucose-dependent Insulinotropic Polypeptide (GIP) Before and After Sitagliptin Treatment

Plasma concentrations of total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GIP were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.

Time frame: 0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose

Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment

Plasma concentrations of active GLP-1, total GLP-1 and total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurements were measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Comparisons were made using Area under the curve (AUC) values and incremental area under the curve (ΔAUC) of active GLP-1, total GLP-1 and total GIP before and after the addition of sitagliptin.

Time frame: 0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose

Secondary Outcomes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.